Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a strong sell rating to a hold rating in a report published on Monday,Zacks.com reports.

KNSA has been the subject of a number of other reports. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Monday, May 4th. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, May 6th. Finally, Citigroup increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $53.34 on Monday. Kiniksa Pharmaceuticals International has a 52 week low of $25.70 and a 52 week high of $59.87. The stock has a market capitalization of $4.10 billion, a price-to-earnings ratio of 59.27 and a beta of 0.17. The stock has a fifty day moving average of $48.98 and a 200-day moving average of $44.61.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. During the same period in the prior year, the company earned $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at $22,398,541.44. The trade was a 52.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Mark Sheptoff Financial Planning LLC grew its holdings in Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after acquiring an additional 250 shares during the period. Mariner LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after acquiring an additional 266 shares during the period. First Trust Advisors LP grew its holdings in Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after acquiring an additional 293 shares during the period. Virtus Investment Advisers LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock worth $678,000 after acquiring an additional 406 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its holdings in Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.